Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

ZURICH/LONDON (Reuters) – Swiss drugmaker Roche is paying $2.4 billion to buy the rest of Foundation Medicine (FMI) , raising its bet on the U.S. genomic profiling group’s ability to personalize cancer care.

Powered by WPeMatico

Scroll to top